Stephen Kayota, MD
Physical Medicine & Rehabilitation · Virginia Beach, VANPI 1083687099
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,238 of the $3,231 with a category attached, or 69.3%. 18 manufacturers reported payments, led by AbbVie at 37.7% of the total. Reporting peaked in 2021 at $1,458 and has fallen 79.0% since, to $307 in 2025. Among physical medicine & rehabilitation clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $32.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Collegium Pharmaceutical, Inc.$905
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$345
- Averitas Pharma Inc.$112
- Pfizer$97
- GRT US Holding, Inc.$90
- plus $464 from 12 others
Across 37 payments — averaging $3886.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$91K
- Biohaven Pharmaceutical Holding Company Ltd.$53K
What the payments were for
- Travel & lodging$99331%
- Food & beverage$2,23869%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 4 | $1,218 |
| Collegium Pharmaceutical, Inc. | 55 | $905 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $345 |
| Averitas Pharma Inc. | 2 | $112 |
| Pfizer | 4 | $97 |
| GRT US Holding, Inc. | 2 | $90 |
| Tonix Medicines, Inc. | 1 | $84 |
| Nevro Corp. | 1 | $72 |
| Scilex Pharmaceuticals Inc. | 4 | $53 |
| Electronic Waveform Lab, Inc. | 3 | $46 |
| Emergent Biosolutions Inc. | 1 | $45 |
| Biodelivery Sciences International, Inc. | 3 | $45 |
| Kaleo, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Shionogi Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$1,182
How this compares
$3,231 in reported general payments places this provider in the 90th percentile of 231 physical medicine & rehabilitation providers in Virginia.
See all physical medicine & rehabilitation providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 61 | $81,974 |
| OxycontinOxycodone Hcl | 24 | $28,516 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 484 | $13,880 |
| Oxycodone Hcl | 397 | $10,957 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 278 | $7,394 |
| MovantikNaloxegol Oxalate | 17 | $6,892 |
| Fentanyl | 63 | $5,871 |
| Morphine Sulfate ErMorphine Sulfate | 156 | $5,496 |
| Diclofenac Sodium | 64 | $2,506 |
| Gabapentin | 213 | $2,341 |
| Tramadol Hcl ErTramadol Hcl | 30 | $2,198 |
| Lidocaine | 40 | $1,970 |
| Pregabalin | 62 | $1,666 |
| Naloxone Hcl | 23 | $1,556 |
| Morphine Sulfate | 46 | $923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $905 | $81,97461 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 physical medicine & rehabilitation providers in Virginia.
Other physical medicine & rehabilitation in Virginia Beach
- Christopher TrowerVirginia Beach$6K
- Muhammad AmjadVirginia Beach$4K
- Gerry SmithVirginia Beach$1K
- Kovosh DastanWinchester$23K
- Stephanie ClopAldie$16K
- Daniel HellerWarrenton$12K
- Amanda MoranNorfolk$9K
- Abraham CherrickAlexandria$9K
- Mir AliRichmond$8K
- Derek BuckBluefield$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.